← Back to Search

Alkylating agents

Treatment for Lung Cancer

Phase 1
Recruiting
Led By C. Matthew Kinsey, MD, MPH
Research Sponsored by University of Vermont
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18 years or above
Eastern Cooperative Oncology Group (ECOG) performance score 0-2
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 14 days
Awards & highlights

Study Summary

This trial is testing how much cisplatin can be given safely by injecting it into the lungs using a special ultrasound tool.

Eligible Conditions
  • Lung Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~14 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 14 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Dose limiting toxicity

Find a Location

Who is running the clinical trial?

University of VermontLead Sponsor
265 Previous Clinical Trials
3,743,482 Total Patients Enrolled
University of Vermont Medical CenterOTHER
41 Previous Clinical Trials
25,816 Total Patients Enrolled
C. Matthew Kinsey, MD, MPHPrincipal Investigator - University of Vermont
University of Vermont
1 Previous Clinical Trials
10 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment for this clinical trial still open?

"As indicated on clinicaltrials.gov, this medical study is still seeking participants. The trial was first advertised in February of 2020 and the details have been revised as recently as May 2022."

Answered by AI

What is the total number of participants enrolled in this research study?

"Yes, the information on clinicaltrials.gov confirms that this medical experiment is currently welcoming participants. This research first appeared on February 26th 2020 and was most recently modified on May 20th 2022 - with a total of 9 individuals sought from 1 centre."

Answered by AI

Could you elucidate the dangers associated with this treatment?

"Due to the paucity of safety and efficacy data, our team at Power has given this treatment a score of 1 on the corresponding scale."

Answered by AI
~2 spots leftby Mar 2025